A related editorial notes that replacement of as-needed short-acting β2-agonists (SABAs) treatment with as-needed budesonide–formoterol or inhaled glucocorticoid maintenance therapy could reduce such risk of asthma exacerbations by approximately 50% but that not all types of airway inflammation respond equally well to inhaled glucocorticoid therapy.